Drug Trial News

RSS

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

Study involving virtual patients is as effective as traditional clinical trials

A study involving virtual rather than real patients was as effective as traditional clinical trials in evaluating a medical device used to treat brain aneurysms, according to new research.

23 Jun 2021

New study enrolls young adults to evaluate SARS-CoV-2 infection

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

23 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Investigational Alzheimer's drug reduces molecular markers of the disease

An investigational Alzheimer's drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU).

21 Jun 2021

Combination of doxycycline and TB drug treatment reduces the size of lung cavities

Globally, an estimated 10 million people develop tuberculosis (TB) each year and the disease remains a leading cause of death from a single infectious agent. Standard short-course anti-TB treatment still requires a regimen of at least six months of antimicrobial drugs, and drug-resistant TB is an increasing public health threat.

21 Jun 2021

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

18 Jun 2021

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.

18 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

18 Jun 2021

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

16 Jun 2021

SARS-CoV-2 oral vaccine booster shows promise in animal tests

Previous
1
...
55
56
57
58
59
60
61
...
1149
Next

Drug Trial News

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

Study involving virtual patients is as effective as traditional clinical trials

New study enrolls young adults to evaluate SARS-CoV-2 infection

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Investigational Alzheimer's drug reduces molecular markers of the disease

Combination of doxycycline and TB drug treatment reduces the size of lung cavities

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

SARS-CoV-2 oral vaccine booster shows promise in animal tests

UCLA clinical trial shows efficacy of varenicline on heavy-drinking smokers

REGEN-COV antibody cocktail shown to significantly lower SARS-CoV-2 viral load

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

ACTG launches phase 1 HIV cure study evaluating two promising therapies

Local anesthetic procaine inhibits SARS-CoV-2 in vitro

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News